← Back to search
8ygq

Crystal structure of Human TEAD2 in complex with Cobimetinib

Method: X-RAY DIFFRACTION Dmax: 72.5 Å Quality: EXCELLENT
▼

1. Protein Identity and Related Structures Protein Identity & Related Structures

Transcriptional enhancer factor TEF-4

Homo sapiens

UniProt Q15562

State in the Current Structure

Assembly Oligomeric State Construct Mutations and Modifications Ligands, Ions and Associated Components Method and Experimental Conditions Structure Quality
1 Protein homooligomer Homooligomer Protein × 2 PDB declaration: dimeric（2） Consistent with protein copy count Chain A； UniProt 221–446 Chain B； UniProt 221–446 Not recorded PLM PALMITIC ACID × 1 EUI [3,4-BIS(FLUORANYL)-2-[(2-FLUORANYL-4-IODANYL-PHENYL)AMINO]PHENYL]-[3-OXIDANYL-3-[(2S)-PIPERIDIN-2-YL]AZETIDIN-1-YL]METHANONE × 1 X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；0.1 M HEPS pH 7.0, 2.6 M sodium formate Resolution 2.71 Å R-free 0.257

Other States of the Same Protein in the Database

Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.

Other PDB Difference from Current Entry 8YGQ Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Method and Experimental Conditions Structure Quality
3L15 Human Tead2 transcriptional factor Deposited 2009-12-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa） Fragment：C-terminal residues 217-447
Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.4；293 K；0.1 M Tris, 2.5 M Sodium Formate, 100 mM NaCl, 2 mM MgCl2, 1 mM TCEP, 5% (w/v) Glycerol;, pH 8.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.00 Å R-free 0.244
3L15 Human Tead2 transcriptional factor Deposited 2009-12-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa） Fragment：C-terminal residues 217-447
Non-standard monomer：Yes (specific site not provided by mmCIF) GOL GLYCEROL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.4；293 K；0.1 M Tris, 2.5 M Sodium Formate, 100 mM NaCl, 2 mM MgCl2, 1 mM TCEP, 5% (w/v) Glycerol;, pH 8.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.00 Å R-free 0.244
5DQ8 Crystal structure of human transcription factor TEAD2 in complex with flufenamic acid Deposited 2015-09-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa） Fragment：residues 217-447
Not recorded FLF 2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO] BENZOIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.2；293 K；0.1 M HEPES pH 7.2, 2.4 M sodium formate
Resolution 2.31 Å R-free 0.232
5DQ8 Crystal structure of human transcription factor TEAD2 in complex with flufenamic acid Deposited 2015-09-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa） Fragment：residues 217-447
Not recorded FLF 2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO] BENZOIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.2；293 K；0.1 M HEPES pH 7.2, 2.4 M sodium formate
Resolution 2.31 Å R-free 0.232
5DQE Crystal structure of human transcription factor TEAD2 in complex with bromo-fenamic acid Deposited 2015-09-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa） Fragment：residues 217-447
Not recorded 5E4 2-[(3-bromophenyl)amino]benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.2；293 K；0.1 M HEPES pH 7.2 and 2.4 M sodium formate.
Resolution 2.18 Å R-free 0.227
5DQE Crystal structure of human transcription factor TEAD2 in complex with bromo-fenamic acid Deposited 2015-09-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa） Fragment：residues 217-447
Not recorded 5E4 2-[(3-bromophenyl)amino]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.2；293 K；0.1 M HEPES pH 7.2 and 2.4 M sodium formate.
Resolution 2.18 Å R-free 0.227
5EMV Crystal structure of the palmitoylated human TEAD2 transcription factor Deposited 2015-11-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 218–446（229 aa） Fragment：YAP binding domain, unp residues 219-435
Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.3；292 K；1.7-2.1 M Sodium Formate
Resolution 2.00 Å R-free 0.231
5EMV Crystal structure of the palmitoylated human TEAD2 transcription factor Deposited 2015-11-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 218–446（229 aa） Fragment：YAP binding domain, unp residues 219-435
Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.3；292 K；1.7-2.1 M Sodium Formate
Resolution 2.00 Å R-free 0.231
5HGU Crystal structure of human transcription factor TEAD2 in complex with palmitate Deposited 2016-01-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa） Fragment：residues 217-447
Not recorded PLM PALMITIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 7.2；293 K；0.1 M HEPES pH 7.2, 2.4 M sodium formate
Resolution 2.05 Å R-free 0.222
5HGU Crystal structure of human transcription factor TEAD2 in complex with palmitate Deposited 2016-01-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa） Fragment：residues 217-447
Not recorded PLM PALMITIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 7.2；293 K；0.1 M HEPES pH 7.2, 2.4 M sodium formate
Resolution 2.05 Å R-free 0.222
6CDY Crystal structure of TEAD complexed with its inhibitor Deposited 2018-02-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded EY1 2-[(4H-1,2,4-triazol-3-yl)sulfanyl]-N-{4-[(3s,5s,7s)-tricyclo[3.3.1.1~3,7~]decan-1-yl]phenyl}acetamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.2；293 K；0.1 M Hepes, pH 7.2, 2.4 M sodium formate.
Resolution 2.32 Å R-free 0.255
6CDY Crystal structure of TEAD complexed with its inhibitor Deposited 2018-02-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded EY1 2-[(4H-1,2,4-triazol-3-yl)sulfanyl]-N-{4-[(3s,5s,7s)-tricyclo[3.3.1.1~3,7~]decan-1-yl]phenyl}acetamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.2；293 K；0.1 M Hepes, pH 7.2, 2.4 M sodium formate.
Resolution 2.32 Å R-free 0.255
6E5G Crystal structure of human TEAD2-Yap binding domain covalently bound to an allosteric regulator Deposited 2018-07-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 220–450（231 aa）
Not recorded HUY 1-(2-{[3-(trifluoromethyl)phenyl]amino}phenyl)ethan-1-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；294 K；2.4-2.8 M sodium formate, HEPES, pH 7.2- 7.4
Resolution 2.43 Å R-free 0.268
6E5G Crystal structure of human TEAD2-Yap binding domain covalently bound to an allosteric regulator Deposited 2018-07-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 220–450（231 aa）
Not recorded HUY 1-(2-{[3-(trifluoromethyl)phenyl]amino}phenyl)ethan-1-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；294 K；2.4-2.8 M sodium formate, HEPES, pH 7.2- 7.4
Resolution 2.43 Å R-free 0.268
6S60 Crystal structure of hTEAD2 in complex with a trisubstituted pyrazole inhibitor Deposited 2019-07-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；2.8M sodium formate
Resolution 2.00 Å R-free 0.228
6S60 Crystal structure of hTEAD2 in complex with a trisubstituted pyrazole inhibitor Deposited 2019-07-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded MYR MYRISTIC ACID × 1 KX8 4-[3-(3,4-dichlorophenyl)-4-[(phenylmethyl)carbamoyl]pyrazol-1-yl]butanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；2.8M sodium formate
Resolution 2.00 Å R-free 0.228
6S64 Crystal structure of hTEAD2 in complex with a trisubstituted pyrazole inhibitor Deposited 2019-07-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；2.8M sodium formate
Resolution 2.22 Å R-free 0.259
6S64 Crystal structure of hTEAD2 in complex with a trisubstituted pyrazole inhibitor Deposited 2019-07-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded PLM PALMITIC ACID × 1 KXE 3-[3-(3,4-dichlorophenyl)-4-[(phenylmethyl)carbamoyl]pyrazol-1-yl]propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；2.8M sodium formate
Resolution 2.22 Å R-free 0.259
6S66 Crystal structure of hTEAD2 in complex with a trisubstituted pyrazole inhibitor Deposited 2019-07-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；2.8M sodium formate
Resolution 2.20 Å R-free 0.262
6S66 Crystal structure of hTEAD2 in complex with a trisubstituted pyrazole inhibitor Deposited 2019-07-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded MYR MYRISTIC ACID × 1 KWW 1-(2-azanylethyl)-3-(3,4-dichlorophenyl)-~{N}-(phenylmethyl)pyrazole-4-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；2.8M sodium formate
Resolution 2.20 Å R-free 0.262
6S69 Crystal structure of hTEAD2 in complex with a trisubstituted pyrazole inhibitor Deposited 2019-07-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；2.8M sodium formate
Resolution 2.15 Å R-free 0.255
6S69 Crystal structure of hTEAD2 in complex with a trisubstituted pyrazole inhibitor Deposited 2019-07-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded MYR MYRISTIC ACID × 1 KX5 3-[3-(3,4-dichlorophenyl)-4-(2-phenylethylcarbamoyl)pyrazol-1-yl]propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；2.8M sodium formate
Resolution 2.15 Å R-free 0.255
6S6J Crystal structure of hTEAD2 in complex with a trisubstituted pyrazole inhibitor Deposited 2019-07-03 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 217–447（231 aa）
Chain B 217–447（231 aa）
Not recorded MYR MYRISTIC ACID × 2 KXH ethyl 1-(4-azanylbutyl)-3-(3,4-dichlorophenyl)pyrazole-4-carboxylate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；2.8M sodium formate
Resolution 2.10 Å R-free 0.231
6UYB Crystal structure of TEAD2 bound to Compound 1 Deposited 2019-11-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 221–451（231 aa）
Not recorded GOL GLYCEROL × 1 QSJ (3R,4R)-1-{3-[(E)-2-(4-chlorophenyl)ethenyl]-4-methoxy-5-methylphenyl}-3,4-dihydroxypyrrolidin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；292 K；200 mM potassium/sodium tartrate pH 6.5 20% PEG 3350
Resolution 1.54 Å R-free 0.232
6UYB Crystal structure of TEAD2 bound to Compound 1 Deposited 2019-11-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 221–451（231 aa）
Not recorded QSJ (3R,4R)-1-{3-[(E)-2-(4-chlorophenyl)ethenyl]-4-methoxy-5-methylphenyl}-3,4-dihydroxypyrrolidin-2-one × 1 TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；292 K；200 mM potassium/sodium tartrate pH 6.5 20% PEG 3350
Resolution 1.54 Å R-free 0.232
6UYC Crystal structure of TEAD2 bound to Compound 2 Deposited 2019-11-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 221–451（231 aa）
Not recorded QLV N-{5-[(E)-2-(4,4-difluorocyclohexyl)ethenyl]-6-methoxypyridin-3-yl}methanesulfonamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；292 K；200 mM potassium/sodium tartrate pH 6.5 20% PEG 3350
Resolution 1.66 Å R-free 0.216
6UYC Crystal structure of TEAD2 bound to Compound 2 Deposited 2019-11-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 221–451（231 aa）
Not recorded QLV N-{5-[(E)-2-(4,4-difluorocyclohexyl)ethenyl]-6-methoxypyridin-3-yl}methanesulfonamide × 1 TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；292 K；200 mM potassium/sodium tartrate pH 6.5 20% PEG 3350
Resolution 1.66 Å R-free 0.216
6VAH Crystal structure of human TEAD2 transcription factor in complex with Flufenamic acid derivative Deposited 2019-12-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded QZ1 2-fluoro-6-[(3-hexylphenyl)amino]benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；3.5M Na Formate, and 0.1M Bis-Tris Propane pH7.0
Resolution 2.11 Å R-free 0.242
6VAH Crystal structure of human TEAD2 transcription factor in complex with Flufenamic acid derivative Deposited 2019-12-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded QZ1 2-fluoro-6-[(3-hexylphenyl)amino]benzoic acid × 1 UNX UNKNOWN LIGAND × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；3.5M Na Formate, and 0.1M Bis-Tris Propane pH7.0
Resolution 2.11 Å R-free 0.242
7OYJ Crystal structure of hTEAD2 in complex with fragment at the interface 2 Deposited 2021-06-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded PLM PALMITIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；2.8M sodium formate
Resolution 1.91 Å R-free 0.222
7OYJ Crystal structure of hTEAD2 in complex with fragment at the interface 2 Deposited 2021-06-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded PLM PALMITIC ACID × 1 3DI 3-(1~{H}-pyrazol-5-yl)aniline × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；2.8M sodium formate
Resolution 1.91 Å R-free 0.222
7T2J Crystal Structure of TEAD2 in a covalent complex with TED-642 Deposited 2021-12-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded E8Y 4-[3-(trifluoromethyl)anilino]-1,3-dihydro-2H-isoindole-2-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；Sodium Formate 1.8 - 2.4 M Hepes pH 7.2 - 7.4
Resolution 2.70 Å R-free 0.279
7T2J Crystal Structure of TEAD2 in a covalent complex with TED-642 Deposited 2021-12-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded E8Y 4-[3-(trifluoromethyl)anilino]-1,3-dihydro-2H-isoindole-2-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；Sodium Formate 1.8 - 2.4 M Hepes pH 7.2 - 7.4
Resolution 2.70 Å R-free 0.279
7T2K Crystal Structure of TEAD2 in a covalent complex with TED-661 Deposited 2021-12-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded ED0 4-[2-(trifluoromethyl)anilino]-1,3-dihydro-2H-isoindole-2-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；Sodium Formate 1.8 M - 2.4 M Hepes pH 7.2 - 7.4
Resolution 2.34 Å R-free 0.286
7T2K Crystal Structure of TEAD2 in a covalent complex with TED-661 Deposited 2021-12-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded ED0 4-[2-(trifluoromethyl)anilino]-1,3-dihydro-2H-isoindole-2-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；Sodium Formate 1.8 M - 2.4 M Hepes pH 7.2 - 7.4
Resolution 2.34 Å R-free 0.286
7T2L Crystal Structure of TEAD2 in a covalent complex with TED-662 Deposited 2021-12-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；Sodium Formate 1.8M - 2.4M HEPES, pH 7.2-7.4
Resolution 2.15 Å R-free 0.257
7T2L Crystal Structure of TEAD2 in a covalent complex with TED-662 Deposited 2021-12-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded EFI (3aR,4R,7aS)-4-[3-(trifluoromethyl)anilino]octahydro-2H-isoindole-2-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；Sodium Formate 1.8M - 2.4M HEPES, pH 7.2-7.4
Resolution 2.15 Å R-free 0.257
7T2M Crystal Structure of TEAD2 in a covalent complex with TED-664 Deposited 2021-12-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded EGK (3aR,4R,7aS)-4-[2-(trifluoromethyl)anilino]octahydro-2H-isoindole-2-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；Sodium Formate 1.8M - 2.4M HEPES pH 7.2 - 7.4
Resolution 2.81 Å R-free 0.279
7T2M Crystal Structure of TEAD2 in a covalent complex with TED-664 Deposited 2021-12-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；Sodium Formate 1.8M - 2.4M HEPES pH 7.2 - 7.4
Resolution 2.81 Å R-free 0.279
7TYP TEAD2 bound to GNE-7883 Deposited 2022-02-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 KUR (8S)-5-(4-cyclohexylphenyl)-3-[3-(fluoromethyl)azetidine-1-carbonyl]-2-(3-methylpyrazin-2-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；0.2 M Na/K Tartrate, 0.1 M Bis Tris pH 6.5, 35% PEG 3350
Resolution 1.60 Å R-free 0.216
7TYP TEAD2 bound to GNE-7883 Deposited 2022-02-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded KUR (8S)-5-(4-cyclohexylphenyl)-3-[3-(fluoromethyl)azetidine-1-carbonyl]-2-(3-methylpyrazin-2-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；0.2 M Na/K Tartrate, 0.1 M Bis Tris pH 6.5, 35% PEG 3350
Resolution 1.60 Å R-free 0.216
7TYQ TEAD2 bound to Compound 1 Deposited 2022-02-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded KUI ethyl (8S)-7-oxo-5-[4-(trifluoromethyl)phenyl]-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；0.2 M Na/K Tartrate, 0.1 M Bis Tris pH 6.5, 35% PEG 3350
Resolution 1.88 Å R-free 0.247
7TYQ TEAD2 bound to Compound 1 Deposited 2022-02-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded KUI ethyl (8S)-7-oxo-5-[4-(trifluoromethyl)phenyl]-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；0.2 M Na/K Tartrate, 0.1 M Bis Tris pH 6.5, 35% PEG 3350
Resolution 1.88 Å R-free 0.247
7TYU TEAD2 bound to Compound 2 Deposited 2022-02-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded KTF (3R)-1-[(8S)-5-(4-cyclohexylphenyl)-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbonyl]pyrrolidine-3-carbonitrile × 1 TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；0.2 M Na/K Tartrate, 0.1 M Bis Tris pH 6.5, 35% PEG 3350
Resolution 1.78 Å R-free 0.230
7TYU TEAD2 bound to Compound 2 Deposited 2022-02-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded KTF (3R)-1-[(8S)-5-(4-cyclohexylphenyl)-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbonyl]pyrrolidine-3-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；0.2 M Na/K Tartrate, 0.1 M Bis Tris pH 6.5, 35% PEG 3350
Resolution 1.78 Å R-free 0.230
8CUH Crystal structure of human TEAD2 complexed with its inhibitor TM2. Deposited 2022-05-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded P0I 4-[3-(2-cyclohexylethoxy)benzoyl]-N-phenylpiperazine-1-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.2；293 K；0.1 M Hepes, pH 7.2, 2.4 M sodium formate.
Resolution 2.40 Å R-free 0.235
8CUH Crystal structure of human TEAD2 complexed with its inhibitor TM2. Deposited 2022-05-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded P0I 4-[3-(2-cyclohexylethoxy)benzoyl]-N-phenylpiperazine-1-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.2；293 K；0.1 M Hepes, pH 7.2, 2.4 M sodium formate.
Resolution 2.40 Å R-free 0.235
8E1O Crystal structure of hTEAD2 bound to a methoxypyridine lipid pocket binder Deposited 2022-08-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Mutation：UNP residues 217-447 TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 Y2S 5-methoxy-N-({3-[2-(methylamino)-2-oxoethyl]phenyl}methyl)-4-{(E)-2-[trans-4-(trifluoromethyl)cyclohexyl]ethenyl}pyridine-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；292 K；200 mM potassium/sodium tartrate, pH 6.5, 20% PEG3350
Resolution 2.25 Å R-free 0.247
8E1O Crystal structure of hTEAD2 bound to a methoxypyridine lipid pocket binder Deposited 2022-08-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Mutation：UNP residues 217-447 Y2S 5-methoxy-N-({3-[2-(methylamino)-2-oxoethyl]phenyl}methyl)-4-{(E)-2-[trans-4-(trifluoromethyl)cyclohexyl]ethenyl}pyridine-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；292 K；200 mM potassium/sodium tartrate, pH 6.5, 20% PEG3350
Resolution 2.25 Å R-free 0.247
8P29 TEAD2 in complex with an inhibitor Deposited 2023-05-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；2.8M sodium formate
Resolution 2.06 Å R-free 0.240
8P29 TEAD2 in complex with an inhibitor Deposited 2023-05-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded GOL GLYCEROL × 1 WJC 5-methyl-2-[(3-phenylmethoxyphenyl)amino]benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；2.8M sodium formate
Resolution 2.06 Å R-free 0.240
8POJ TEAD2 in complex with an inhibitor Deposited 2023-07-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；2.8M sodium formate
Resolution 2.45 Å R-free 0.268
8POJ TEAD2 in complex with an inhibitor Deposited 2023-07-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded ZUL 4-fluoranyl-2-[(3-phenylphenyl)amino]benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；2.8M sodium formate
Resolution 2.45 Å R-free 0.268
8POM TEAD2 in complex with an inhibitor Deposited 2023-07-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded ZUP 2-[[3-(2-phenylethoxy)phenyl]amino]pyridine-3-carboxylic acid × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；2.8M sodium formate
Resolution 1.95 Å R-free 0.248
8POM TEAD2 in complex with an inhibitor Deposited 2023-07-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded ZUP 2-[[3-(2-phenylethoxy)phenyl]amino]pyridine-3-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；2.8M sodium formate
Resolution 1.95 Å R-free 0.248
8PON TEAD2 in complex with an inhibitor Deposited 2023-07-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；2.8M sodium formate
Resolution 2.20 Å R-free 0.254
8PON TEAD2 in complex with an inhibitor Deposited 2023-07-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded ZUT 4-fluoranyl-2-[(3-phenylmethoxyphenyl)amino]benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；2.8M sodium formate
Resolution 2.20 Å R-free 0.254
8PUX TEAD2 with a covalent inhibitor Deposited 2023-07-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；2.8M sodium formate
Resolution 2.05 Å R-free 0.261
8PUX TEAD2 with a covalent inhibitor Deposited 2023-07-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded B3F ~{N}-[2-[(3-pentoxyphenyl)amino]phenyl]propanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；2.8M sodium formate
Resolution 2.05 Å R-free 0.261
8PUY TEAD2 with a covalent inhibitor Deposited 2023-07-17 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 217–447（231 aa）
Chain B 217–447（231 aa）
Not recorded F3Y ~{N}-[3-[(3-pentoxyphenyl)amino]phenyl]propanamide × 1 MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；2.8M sodium formate
Resolution 2.20 Å R-free 0.252
8RXL TEAD2 with an inhibitor Deposited 2024-02-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 216–447（232 aa）
Not recorded A1H3Z 4-(5-phenylmethoxy-1~{H}-indol-3-yl)butan-2-one × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；2.8M sodium formate
Resolution 2.29 Å R-free 0.271
8RXL TEAD2 with an inhibitor Deposited 2024-02-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 216–447（232 aa）
Not recorded A1H3Z 4-(5-phenylmethoxy-1~{H}-indol-3-yl)butan-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；2.8M sodium formate
Resolution 2.29 Å R-free 0.271
8RXP TEAD2 with an inhibitor Deposited 2024-02-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded A1H3Y 2-(5-phenylmethoxy-1~{H}-indol-3-yl)ethanol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；2.8M sodium formate
Resolution 2.49 Å R-free 0.274
8RXP TEAD2 with an inhibitor Deposited 2024-02-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded A1H3Y 2-(5-phenylmethoxy-1~{H}-indol-3-yl)ethanol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；2.8M sodium formate
Resolution 2.49 Å R-free 0.274
8RXQ TEAD2 with an inhibitor Deposited 2024-02-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded A1H3X ethyl (~{E})-3-(5-phenylmethoxy-1~{H}-indol-3-yl)prop-2-enoate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；288 K；2.8M sodium formate
Resolution 2.63 Å R-free 0.269
8RXQ TEAD2 with an inhibitor Deposited 2024-02-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；288 K；2.8M sodium formate
Resolution 2.63 Å R-free 0.269
8RXV TEAD2 with an inhibitor Deposited 2024-02-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded A1H3W ~{N}-[2-(5-phenylmethoxy-1~{H}-indol-3-yl)ethyl]methanesulfonamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；288 K；2.8M sodium formate
Resolution 2.05 Å R-free 0.297
8RXV TEAD2 with an inhibitor Deposited 2024-02-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded A1H3W ~{N}-[2-(5-phenylmethoxy-1~{H}-indol-3-yl)ethyl]methanesulfonamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；288 K；2.8M sodium formate
Resolution 2.05 Å R-free 0.297
8RYC TEAD2 with an inhibitor Deposited 2024-02-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded A1H32 5-phenylmethoxy-1~{H}-indole × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；288 K；2.8M sodium formate
Resolution 2.09 Å R-free 0.249
8RYC TEAD2 with an inhibitor Deposited 2024-02-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；288 K；2.8M sodium formate
Resolution 2.09 Å R-free 0.249
9NEO TEAD2 YAP binding domain (YBD) Deposited 2025-02-20 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 217–447（231 aa） Fragment：UNP Residues 217-447
Chain B 217–447（231 aa） Fragment：UNP Residues 217-447
Not recorded A1BXX (3R)-3-ethenyl-3-(5-{3-[4-(trifluoromethyl)anilino]pyridin-2-yl}-1,3,4-oxadiazol-2-yl)pyrrolidin-2-one × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293.15 K；3.1M Na Formate, 100mM HEPES pH 7.5
Resolution 3.13 Å R-free 0.316
9Q1M Crystal structure of human TEAD2 Yap binding domain covalently bound to an allosteric regulator Deposited 2025-08-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded IU8 1-{4-[3-(trifluoromethyl)anilino]-2H-isoindol-2-yl}propan-1-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；Sodium Formate 1.8 - 2.4 M Hepes pH 7.2 - 7.4
Resolution 2.60 Å R-free 0.261
9Q1M Crystal structure of human TEAD2 Yap binding domain covalently bound to an allosteric regulator Deposited 2025-08-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded IU8 1-{4-[3-(trifluoromethyl)anilino]-2H-isoindol-2-yl}propan-1-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；Sodium Formate 1.8 - 2.4 M Hepes pH 7.2 - 7.4
Resolution 2.60 Å R-free 0.261
9Q1N Crystal structure of human TEAD2-Yap binding domain covalently bound to an allosteric regulator Deposited 2025-08-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded EI2 1-{4-[4-(trifluoromethyl)anilino]-1,3-dihydro-2H-isoindol-2-yl}propan-1-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；Sodium Formate 1.8M - 2.4M HEPES pH 7.2 - 7.4
Resolution 2.13 Å R-free 0.248
9Q1N Crystal structure of human TEAD2-Yap binding domain covalently bound to an allosteric regulator Deposited 2025-08-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded EI2 1-{4-[4-(trifluoromethyl)anilino]-1,3-dihydro-2H-isoindol-2-yl}propan-1-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；Sodium Formate 1.8M - 2.4M HEPES pH 7.2 - 7.4
Resolution 2.13 Å R-free 0.248
9Q1O Crystal structure of human TEAD2-Yap binding domain covalently bound to an allosteric regulator Deposited 2025-08-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded EI6 1-{(3aS,4R,7aR)-4-[4-(trifluoromethyl)anilino]octahydro-2H-isoindol-2-yl}propan-1-one × 1 FMT FORMIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；Sodium Formate 1.8M - 2.4M HEPES pH 7.2 - 7.4
Resolution 2.26 Å R-free 0.266
9Q1O Crystal structure of human TEAD2-Yap binding domain covalently bound to an allosteric regulator Deposited 2025-08-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded EI6 1-{(3aS,4R,7aR)-4-[4-(trifluoromethyl)anilino]octahydro-2H-isoindol-2-yl}propan-1-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；Sodium Formate 1.8M - 2.4M HEPES pH 7.2 - 7.4
Resolution 2.26 Å R-free 0.266
9YK2 Crystal structure of TEAD2 with non-covalent aryl ether inhibitor. Deposited 2025-10-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 217–447（231 aa）
Not recorded A1CXJ (3P)-N-methyl-3-(1-methyl-1H-pyrazol-4-yl)-4-[4-(trifluoromethyl)phenoxy]benzene-1-sulfonamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；21% PEG 3350, 0.15 M NaSO4, 0.1 M Bis-Tris propane (pH 6.5)
Resolution 2.16 Å R-free 0.288
9YK2 Crystal structure of TEAD2 with non-covalent aryl ether inhibitor. Deposited 2025-10-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 217–447（231 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；21% PEG 3350, 0.15 M NaSO4, 0.1 M Bis-Tris propane (pH 6.5)
Resolution 2.16 Å R-free 0.288

41 other PDB entries and 79 assemblies. Open the comparison page and filter oligomeric states

View Construct and Data Evidence
UniProt name TEAD2_HUMAN
Isoform —
PDB entities 1
Chains and sequence ranges Author chain A； PDBConstruct 1–226； UniProt 221–446 Author chain B； PDBConstruct 1–226； UniProt 221–446

The page prioritizes protein identity, the current assembly, associated components, oligomeric state and cross-PDB links. Chain mapping and sequence ranges are retained as data evidence. Internal IDs, import timestamps and assembly operation expressions are maintenance fields and are not shown here.

SAXS scattering curve SAXS Profile

SAXS profile for 8ygq

P(r) Distance Distribution P(r) Distribution

P(r) distribution for 8ygq
Download Download
▼

2. Structure Basics 2. Structure Basics

Entry ID entry_id8ygq
Deposition date deposition_date2024-02-26
Structure title titleCrystal structure of Human TEAD2 in complex with Cobimetinib
Keywords keywordsHippo pathway, TEAD Inhibitor, TRANSCRIPTION; TRANSCRIPTION
Experimental Method methodX-RAY DIFFRACTION
▼

3. SAXS Parameters (CRYSOL theoretical calculation) 3. SAXS Parameters (CRYSOL)

Radius of gyration Rg (Guinier) rg_guinier23.60 Å
Radius of gyration Rg (electron density) rg_electron22.26 Å
Forward intensity I(0) i036049000.00
Molecular weight molecular_weight46813.0 kDa
Excluded volume excluded_volume58808 ų
Envelope volume envelope_volume69975 ų
Hydration-shell volume shell_volume25900 ų
Envelope diameter envelope_diameter75.2 Å
Shell Rg shell_rg29.40 Å
Envelope Rg envelope_rg22.36 Å
Shape Rg shape_rg22.28 Å
Total Rg total_rg23.09 Å
Total atoms total_atoms3297
Residues n_residues395
Spherical-harmonic order n_harmonics20
q range q_range— – 0.5000 Å−1
Data points n_points101
Shell type shell_typedirectional
Solvent electron density solvent_density0.3340 e/ų
Shell contrast contrast_shell0.0300 e/ų
CRYSOL version crysol_version4.1.3
▼

4. P(r) Distance Distribution (GNOM inversion) 4. P(r) Analysis (GNOM)

Maximum dimension Dmax dmax72.5 Å
Rg (real space) rg_real23.47 Å
Rg uncertainty (real space) rg_real_error0.33 Å
I(0) (real space) i0_real3.6050e+07
I(0) uncertainty (real space) i0_real_error4.3580e+05
Rg (reciprocal space) rg_reciprocal23.51 Å
I(0) (reciprocal space) i0_reciprocal36050000.0000
Solution quality estimate total_estimate0.9087
Solution quality rating solution_quality EXCELLENT a EXCELLENT solution
P(r) peaks n_peaks2
Primary peak position r_peak_primary29.4 Å
Skewness Skewness skewness0.171
Kurtosis Kurtosis kurtosis-0.474
Angular range angular_range— – 0.3350 Å−1
Current regularization parameter α current_alpha0.0000
Highest regularization parameter α highest_alpha6389000.0000
Real-space data points n_real_points65
GNOM version gnom_version4.1.3
Quality Criteria quality_criteria AN1: 0.000; Oscil: 0.941; Stabil: 1.000; Sysdev: 1.000; Positv: 1.000; Valcen: 0.994; Smooth: 0.991
▶

5. Crystallography and Experiment 5. Crystallography & Experiment

▶

6. Entities and Polymers Entities & Polymers (3)

▶

8. Citations (1)

▶

9. Files and Curves (10)